Identifying and preventing severe lung complications after stem cell transplants
Official title: Predicting and Preventing Acute Respiratory Distress Syndrome after Hematopoietic Stem Cell Transplantation
Funded at Mayo Clinic Rochester · NIH-10909914 · Data updated 2026-11-12
This study is looking to help patients who are getting a stem cell transplant by finding ways to predict and prevent a serious lung problem called acute respiratory distress syndrome (ARDS), so they can have a smoother recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2021 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $162,415 |
| NIH project number | 5K23HL151671-04 |
| Project ID | NIH-10909914 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients scheduled to undergo hematopoietic stem cell transplantation who may be at risk for developing acute respiratory distress syndrome.
✕Less likely to help
Patients who are not undergoing hematopoietic stem cell transplantation or those who have pre-existing severe lung conditions may not benefit from this research.
What this research studies
This research focuses on improving outcomes for patients undergoing hematopoietic stem cell transplantation (HSCT) by developing methods to predict and prevent acute respiratory distress syndrome (ARDS), a serious lung complication that can occur post-transplant. The study aims to create a risk-prediction model that identifies patients at high risk for ARDS using various pre- and post-transplant factors. Additionally, it will explore the biological mechanisms behind ARDS through metabolomics, which involves analyzing metabolites in the body to understand different patient responses. By addressing these critical gaps, the research seeks to enhance patient care and reduce the incidence of ARDS following HSCT.
Why it matters
Potential benefit: If successful, this research could significantly reduce the occurrence of ARDS in patients undergoing stem cell transplants, leading to better survival rates and improved quality of life.
How similar studies have gone: Previous research has shown promise in using risk-prediction models and metabolomics to address similar complications in other patient populations, indicating potential for success in this novel approach.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Yadav, Hemang — Mayo Clinic Rochester
- Study coordinator: Yadav, Hemang
Related research
Other NIH-funded projects on the same topics.
-
Identifying ARDS patients who may benefit from paralytics guided by high-frequency clinical data
This grant aims to help doctors figure out which adults with ARDS are most likely to benefit from paralytic medications using detailed bedside data and electronic health records.
-
Resilience endotypes and early ARDS detection using biomarkers and AI
A Duke University team is using biomarkers and smart data analysis to detect ARDS early and uncover patterns that predict how patients recover.
-
PAR1’s role in lung lymphatics and a new therapy approach for ARDS
This grant explores how the thrombin receptor PAR1 affects lung lymphatics to understand and ultimately reduce lung injury in ARDS patients.
-
Dead space and inhaled nitric oxide in pediatric ARDS
This project looks at whether measuring dead space and using inhaled nitric oxide can help improve outcomes for children with acute respiratory distress syndrome.
-
Immune, hormone, and muscle energy links to recovery after ARDS
This project looks at why some ARDS survivors have ongoing weakness and how immune, hormone, and muscle energy factors might influence recovery.</n>
-
Understanding why some people with severe lung injury get worse and how to tailor therapy
A patient-focused program that looks at why people develop sepsis-associated ARDS and how their bodies respond, with the goal of guiding better, personalized treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.